drugset / Trial / NCT06344351
A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study includes two stage: dose escalation and dose extension, with a single dose and a multiple dose study. This is a single-center, open, non-randomized, single arm, study to evaluate the safety, tolerability and pharmacokinetics of TQB3006 tables in patients with advanced malignant cancer.
Timeline
- Start
- 2024-04-25
- Primary completion
- 2025-05-20
- Completion
- 2025-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB3006 | Protein / enzyme biologic | 200 mg | Oral |
| Subject | TQB3006 | Protein / enzyme biologic | 1200 mg | Oral |